This article is more than 5 years old. Information may no longer be current.

Bevacizumab shows similar endophthalmitis rates to other intravitreal drugs

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Infectious endophthalmitis occurs after intravitreal injections of bevacizumab at a rate of about one in 1,000, similar to rates seen for other intravitreal drugs, according to a study by researchers in Germany.

Jost B. Jonas, MD, and colleagues at the Ruprecht-Karls-University Heidelberg investigated the incidence of infectious and noninfectious endophthalmitis after 1.5 mg intravitreal injections of Avastin (bevacizumab, Genentech). The study involved 1,218 total injections, including 534 reinjections, performed in 684 eyes with exudative age-related macular degeneration.

Each patient was followed for at least 4 weeks after each injection, the authors noted.

The researchers found that one eye developed infectious endophthalmitis 3 days after a second injection. However, no other patients showed signs of infectious or noninfectious endophthalmitis, the authors reported.

The study is published in the June issue of Journal of Ocular Pharmacology and Therapeutics.